Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
NeoGenomics (NEO)
NASDAQ:NEO
NEO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$10.69 - $19.12
Previous CloseN/A
Volume108.49K
Average Volume (3M)1.22M
Market Cap
$1.52B
Enterprise Value$2.09B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.26
Next Earnings
May 06, 2025EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.62
Shares Outstanding128,461,380
10 Day Avg. Volume1,213,656
30 Day Avg. Volume1,215,437
Standard Deviation0.17
R-Squared0.14
Alpha-0.01
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)2.53
Price to Cash Flow (P/CF)44.20
P/FCF Ratio0.00
Enterprise Value/Market Cap1.37
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit7.21
Enterprise Value/Ebitda-4.76K
Forecast
1Y Price Target
$17.75Price Target Upside49.66% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering12
---
Bulls Say, Bears Say
Bulls Say
Core Business PerformanceThe fundamentals of NEO's core business are sound, with Q4'24 clinical services revenue growth of +15% driven by increases in volume and price.
Product InnovationNEO expects to launch its new NEO Pan Tracer liquid biopsy blood test panel, which may be additive to growth.
Bears Say
Leadership ChangesShares of NEO have pulled back by ~30% following the surprising news that the company's CEO, Chris Smith, will leave both the CEO seat and the Board.
---
Ownership Overview
1.13% Insiders
36.32% Mutual Funds
23.49% Other Institutional Investors
13.09% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
NEO FAQ
What was NeoGenomics’s price range in the past 12 months?
NeoGenomics lowest stock price was $10.69 and its highest was $19.11 in the past 12 months.
What is NeoGenomics’s market cap?
NeoGenomics’s market cap is $1.52B.
When is NeoGenomics’s upcoming earnings report date?
NeoGenomics’s upcoming earnings report date is May 06, 2025 which is in 73 days.
How were NeoGenomics’s earnings last quarter?
NeoGenomics released its earnings results on Feb 18, 2025. The company reported $0.04 earnings per share for the quarter, beating the consensus estimate of $0.029 by $0.011.
Is NeoGenomics overvalued?
According to Wall Street analysts NeoGenomics’s price is currently Undervalued.
Does NeoGenomics pay dividends?
NeoGenomics does not currently pay dividends.
What is NeoGenomics’s EPS estimate?
NeoGenomics’s EPS estimate is >-0.01.
How many shares outstanding does NeoGenomics have?
NeoGenomics has 128,461,380 shares outstanding.
What happened to NeoGenomics’s price movement after its last earnings report?
NeoGenomics reported an EPS of $0.04 in its last earnings report, beating expectations of $0.029. Following the earnings report the stock price went down -14.008%.
Which hedge fund is a major shareholder of NeoGenomics?
Currently, no hedge funds are holding shares in NEO
---
NeoGenomics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$17.75 (49.66% Upside)
$17.75 (49.66% Upside)
Blogger Sentiment
Bullish
NEO Sentiment 100%
Sector Average 71%
Sector Average 71%
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.7%
Last 30 Days ▼ 0.2%
Last 30 Days ▼ 0.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-19.31%
12-Months-Change
Fundamentals
Return on Equity
-8.54%
Trailing 12-Months
Asset Growth
-2.57%
Trailing 12-Months
Company Description
NeoGenomics
NeoGenomics, Inc. is a clinical laboratory, which specializes in cancer genetics diagnostic testing and pharma services. It operates through the following two segments: Clinical and Pharma Services. The Clinical Services segment offers clinical cancer testing services to community-based pathologists. The Pharma Services segments supports pharmaceutical firms in their drug development programs by supporting various clinical trials and research. The Clinical Services Segment provides various clinical testing services to community-based pathology practices, hospital pathology labs and academic centers with reimbursement from various payers including client direct billing, commercial insurance, Medicare and other government payers, and patients. The Pharma Services segment: provides comprehensive testing services in supports pharmaceutical clients' oncology programs from discovery to commercialization. Its services include cytogenetics, fluorescence in-situ hybridization, flow cytometry, immunohistochemistry, anatomic pathology and molecular genetic testing. The company was founded by Michael T. Dent on October 29, 1998 and is headquartered in Fort Myers, FL.
---
NEO Company Deck
---
NEO Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
NeoGenomics demonstrated strong revenue growth and financial improvement, particularly in its NGS segment and adjusted EBITDA. However, challenges in the pharma segment and ongoing legal issues with RaDaR tempered the overall positive performance.Read More>---
NEO Stock 12 Month Forecast
Average Price Target
$17.75
▲(49.66% Upside)
Technical Analysis
Best Analysts Covering NEO
1 Year
1 Year Success Rate
6/12 ratings generated profit
1 Year Average Return
+11.22%
assigned a buy rating 7 months ago
Copying David Westenberg's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +11.22% per trade.
---